Prostatic Specific Antigen and Benign Prostatic Hyperplasia

Atan, Ali; Horn, Thomas; Hansen, Frank; Jakobsen, Henrik; Hald, T

doi:10.3109/00365599609182310

Cited by 9 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some group of people, mixed hyperplasia with equal proportions of both components can be observed, However any correlation between this type of hyperplasia, and serum PSA level has not been detected. [9] Serum PSA level is very important for urologists. Indeed prostate cancer (PCa) is the most frequently type of cancer encountered in men in Europe, and the USA.…”

mentioning

confidence: 99%

How should prostate specific antigen be interpreted?

Atan

Güzel

2014

Turkish Journal of Urology

Self Cite

View full text Add to dashboard Cite

Since from its clinical introduction to the present time, measurement of serum prostate specific antigen (PSA) level is one of the most widely used tests in urology practice. Initially, the upper limit for PSA was 4 ng/mL, but today, a reduction for the upper limit is recommended to 2.5-3 ng/mL for patients between 60 and 65 years of age and younger. On the use of PSA as a screening test for prostate cancer, there are differences of opinion. However, it is a recommended test in the evaluation and monitoring of the risky group for prostate cancer. In conclusion PSA test should be performed at appropriate intervals for appropriate people with an appropriate age, after informing the patient about the test in detail.

show abstract

mentioning

confidence: 99%

How should prostate specific antigen be interpreted?

Atan

Güzel

2014

Turkish Journal of Urology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Kefi et al [14] reported that there was no difference between the patients with and without AUR with respect to prostatic volume and the weight of resected prostatic tissue; however, there was a significant difference with respect to the tPSA level. Tuncel et al [15] and Atan et al [16] also found that the serum tPSA level was an important risk factor in AUR etiology, whereas the prostatic size was not. Our findings were opposite to theirs, both in terms of tPSA and Rt.…”

Section: Discussionmentioning

confidence: 99%

The risk factors for acute urinary retention in patients with benign prostatic hyperplasia

Demirel¹,

Gökkaya²,

Özden³

et al. 2012

Turkish Journal of Urology

View full text Add to dashboard Cite

ÖZETAmaç: Akut üriner retansiyonun (AUR) ensık sebebi benign prostat hiperplazisidir(BPH). AUR'un etyolojisini ayrıntılı bir şekilde araştırmak için, BPH'lı hastalarda AUR ve histolojik prostatik inflamasyon ilişkisini değerlendirdik. Gereç ve Yöntem:Çalışmaya Ocak-Aralık 2008 tarihleri arasında BPH'ne bağlı AUR veya alt üriner sistem semptomları (AÜSS) nedeniyle trans üretral rezeksiyon-prostat (TURP) yapılan 226 hasta dahil edildi. Hastalar AUR(+) (n=89) ve AUR(-) (n=137) olmak üzere 2 gruba ayrıldı. Bu iki grup; yaşlarına, rezeke edilen prostat dokusu ağırlığına (Rt), total prostat spesifik antijen (tPSA) düzeylerine ve prostat dokusu patolojisinde inflamasyon varlığına göre karşılaştırıldı. AUR için bağımsız risk faktörleri lojistik regresyon analizi ile değerlendirildi ve P değeri <0.005 ise anlamlı olarak kabul edildi. Bulgular: Bu 226 hastanın ortalama yaşları 67.7±7.7 yıl, ortalama tPSA değeri 6.45±4.97 ng/ml, ortalama rezeke edilen prostat ağırlığı (Rt) 25.47±21.77 gr. idi. Ortalama yaş ve ortalama Rt, AUR(+) grubunda diğer gruba göre anlamlı olarak daha fazla idi (p<0.0001 ve p= 0.031). Prostatik inflamasyonu olan hastalarda AUR gelişme riski olmayanlara göre anlamlı olarak daha yüksek bulundu (p= 0.049). Yapılan lojistik regresyon analizinde, 70 yaşın üzerinde, 25 gr'dan fazla doku çıkarılması ve prostatik inflamasyon varlığı AUR gelişiminde bağımsız risk faktörleri olarak bulundu.Sonuç: Sonuçlarımız göstermektedir ki; BPH'li hastalarda 70 yaşın üzerinde olmak, 25 gr'dan fazla doku çıkarılması ve prostatik inflamasyon varlığı AUR gelişiminde bağımsız risk faktörleridir.Anahtar sözcükler: Akut üriner retansiyon; benign prostat hiperplazisi; alt üriner sistem semptomları; prostat spesifik antijen. ABSTRACT Objective:The most common cause of obstructive acute urinary retention (AUR) is benign prostatic hyperplasia (BPH). To investigate the etiology of AUR, we evaluated the relationship between AUR and histological prostatic inflammation in patients with BPH. Materials and Methods:Between January and December of 2008, 226 patients who underwent transurethral resection of prostate (TURP) for AUR or lower urinary tract symptoms (LUTS) as a result of BPH were included in the study. Patients were classified into AUR(+) (n=89) and AUR(-) (n=137) groups. The two groups were compared along the following dimensions: age, weight of resected prostatic tissue (Rt), total prostate specific antigen (tPSA) levels and the presence of inflammation in the prostatic pathology. Independent risk factors for AUR were evaluated using logistic regression analysis. P values <0.05 were considered significant. Results:The mean age of the 226 patients was 67.7±7.7 years; the mean tPSA level was 6.45±4.97 ng/ml; and the mean weight of resected prostatic tissue (Rt) was 25.47±21.77 g. The mean age and Rt of the AUR(+) group were significantly higher than those of the AUR(-) group (p<0.0001 and p= 0.031, respectively). The odds of AUR were significantly higher in the patients with inflammation than in those without (p= 0.049). An age ...

show abstract

Re: Prostate Tissue Composition and Response to Finasteride in Men With Symptomatic Benign Prostatic Hyperplasia

Atan

1998

Journal of Urology

View full text Add to dashboard Cite

Prostatic Specific Antigen and Benign Prostatic Hyperplasia

Cited by 9 publications

References 13 publications

How should prostate specific antigen be interpreted?

How should prostate specific antigen be interpreted?

The risk factors for acute urinary retention in patients with benign prostatic hyperplasia

Re: Prostate Tissue Composition and Response to Finasteride in Men With Symptomatic Benign Prostatic Hyperplasia

Contact Info

Product

Resources

About